Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
Creighton University
mi
from
Omaha, NE
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
Creighton University
mi
from
Omaha, NE
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
University of California at San Francisco
mi
from
San Francisco, CA
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
Barbara Davis Center for Childhood Diabetes, University of Colorado
mi
from
Aurora, CO
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
Barbara Davis Center for Childhood Diabetes, University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
Indiana University
mi
from
Indianapolis, IN
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
University of Iowa Hospital and Clinics
mi
from
Iowa City, IA
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
University of Iowa Hospital and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
University of Maryland
mi
from
Baltimore, MD
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
Massachusetts General Hospital
mi
from
Boston, MA
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
University of North Carolina
mi
from
Durham, NC
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
University of North Carolina
mi
from
Durham, NC
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated:  6/12/2017
University of Arizona
mi
from
Tucson, AZ
Inducing Remission in Type 1 Diabetes With Alefacept
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Status: Enrolling
Updated: 6/12/2017
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK716155 in Healthy Adult Female Subjects
Status: Enrolling
Updated:  6/13/2017
GSK Investigational Site
mi
from
Austin, TX
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK716155 in Healthy Adult Female Subjects
Status: Enrolling
Updated: 6/13/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status: Enrolling
Updated:  6/13/2017
GSK Investigational Site
mi
from
Anniston, AL
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status: Enrolling
Updated: 6/13/2017
GSK Investigational Site
mi
from
Anniston, AL
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status: Enrolling
Updated:  6/13/2017
GSK Investigational Site
mi
from
Miami Gardens, FL
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status: Enrolling
Updated: 6/13/2017
GSK Investigational Site
mi
from
Miami Gardens, FL
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status: Enrolling
Updated:  6/13/2017
GSK Investigational Site
mi
from
Miami, FL
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status: Enrolling
Updated: 6/13/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status: Enrolling
Updated:  6/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status: Enrolling
Updated: 6/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression
Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression
Status: Enrolling
Updated:  6/14/2017
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression
Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression
Status: Enrolling
Updated: 6/14/2017
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics
A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  6/19/2017
GSK Investigational Site
mi
from
Phoenix, AZ
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics
A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 6/19/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics
A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  6/19/2017
GSK Investigational Site
mi
from
Saint Paul, MN
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics
A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 6/19/2017
GSK Investigational Site
mi
from
Saint Paul, MN
Click here to add this to my saved trials
First Time in Human Study Using GSK2330672
A First Time in Human, Single Blind, Randomized, Placebo-controlled,Dose Escalating Crossover Study to Evaluate the Safety,Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Healthy Volunteers
Status: Enrolling
Updated:  6/19/2017
GSK Investigational Site
mi
from
Minneapolis, MN
First Time in Human Study Using GSK2330672
A First Time in Human, Single Blind, Randomized, Placebo-controlled,Dose Escalating Crossover Study to Evaluate the Safety,Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Healthy Volunteers
Status: Enrolling
Updated: 6/19/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Drug Interaction Study With Albiglutide and Warfarin
An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects
Status: Enrolling
Updated:  6/21/2017
GSK Investigational Site
mi
from
Austin, TX
A Drug Interaction Study With Albiglutide and Warfarin
An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects
Status: Enrolling
Updated: 6/21/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers
A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks
Status: Enrolling
Updated:  6/26/2017
University of Arizona
mi
from
Tucson, AZ
NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers
A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks
Status: Enrolling
Updated: 6/26/2017
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers
A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks
Status: Enrolling
Updated:  6/26/2017
Center for Clinical Research
mi
from
Castro Valley, CA
NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers
A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks
Status: Enrolling
Updated: 6/26/2017
Center for Clinical Research
mi
from
Castro Valley, CA
Click here to add this to my saved trials
NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers
A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks
Status: Enrolling
Updated:  6/26/2017
Ankle and Foot Centers of Georgia
mi
from
Newnan, GA
NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers
A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks
Status: Enrolling
Updated: 6/26/2017
Ankle and Foot Centers of Georgia
mi
from
Newnan, GA
Click here to add this to my saved trials
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
Effect of Ethanol Intoxication on the Anti-hypoglycemic Action of Glucagon
Status: Enrolling
Updated:  6/27/2017
Massachusetts General Hospital Diabetes Research Center
mi
from
Boston, MA
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
Effect of Ethanol Intoxication on the Anti-hypoglycemic Action of Glucagon
Status: Enrolling
Updated: 6/27/2017
Massachusetts General Hospital Diabetes Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  6/28/2017
Miami Research Associates
mi
from
South Miami, FL
A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 6/28/2017
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  6/28/2017
mi
from
Singapore,
A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 6/28/2017
mi
from
Singapore,
Click here to add this to my saved trials
Interactive Spaced Education to Optimize Diabetes Care
Interactive Spaced Education to Optimize Diabetes Care
Status: Enrolling
Updated:  7/11/2017
Veterans Affairs Boston Healthcare System
mi
from
Boston, MA
Interactive Spaced Education to Optimize Diabetes Care
Interactive Spaced Education to Optimize Diabetes Care
Status: Enrolling
Updated: 7/11/2017
Veterans Affairs Boston Healthcare System
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers
A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2374697 in Healthy Volunteers
Status: Enrolling
Updated:  7/24/2017
GSK Investigational Site
mi
from
Minneapolis, MN
A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers
A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2374697 in Healthy Volunteers
Status: Enrolling
Updated: 7/24/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD
Dietary Nitrate to Augment Exercise Training Benefits in Subjects With Type II Diabetes (DM) and Peripheral Arterial Disease (PAD)
Status: Enrolling
Updated:  7/26/2017
Duke Diet & Fitness Center
mi
from
Durham, NC
Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD
Dietary Nitrate to Augment Exercise Training Benefits in Subjects With Type II Diabetes (DM) and Peripheral Arterial Disease (PAD)
Status: Enrolling
Updated: 7/26/2017
Duke Diet & Fitness Center
mi
from
Durham, NC
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Elite Research Institute
mi
from
Miami, FL
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Elite Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.)
mi
from
Miramar, FL
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.)
mi
from
Miramar, FL
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
ICON Clinical Pharmacology, LLC
mi
from
Omaha, NE
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
ICON Clinical Pharmacology, LLC
mi
from
Omaha, NE
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Healthcare Discoveries, LLC d/b/a ICON Development Solutions
mi
from
San Antonio, TX
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Healthcare Discoveries, LLC d/b/a ICON Development Solutions
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin
A Multicenter, Open-label Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin 100mg qd Plus Metformin 1000mg Bid in Drug Naive Patients With Type 2 Diabetes With Very Poor Glycemic Control
Status: Enrolling
Updated:  8/1/2017
'Diabetes & Glandular Disease Research Associates, P.A.
mi
from
San Antonio, TX
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin
A Multicenter, Open-label Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin 100mg qd Plus Metformin 1000mg Bid in Drug Naive Patients With Type 2 Diabetes With Very Poor Glycemic Control
Status: Enrolling
Updated: 8/1/2017
'Diabetes & Glandular Disease Research Associates, P.A.
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.
A Randomised, 3-Period, 3-Treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Fed-state Bioequivalence of a Triple Fixed-Combination Drug Product of 2.5 mg Saxagliptin / 5 mg Dapagliflozin / 1000 mg Metformin XR and 5 mg Saxagliptin / 10 mg Dapagliflozin / 1000 mg Metformin XR Relative to Individual Components (Onglyza® and XIGDUO® XR) Co-administered to Healthy Subjects
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Baltimore, MD
A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.
A Randomised, 3-Period, 3-Treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Fed-state Bioequivalence of a Triple Fixed-Combination Drug Product of 2.5 mg Saxagliptin / 5 mg Dapagliflozin / 1000 mg Metformin XR and 5 mg Saxagliptin / 10 mg Dapagliflozin / 1000 mg Metformin XR Relative to Individual Components (Onglyza® and XIGDUO® XR) Co-administered to Healthy Subjects
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment
Status: Enrolling
Updated:  8/3/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment
Status: Enrolling
Updated: 8/3/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease
Status: Enrolling
Updated:  8/7/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease
Status: Enrolling
Updated: 8/7/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Tailored Diabetes Self-Management Resources
Family-Centered Tailoring of Pediatric Diabetes Self-Management Resources
Status: Enrolling
Updated:  8/10/2017
University of Wisconsin-Madison
mi
from
Madison, WI
Tailored Diabetes Self-Management Resources
Family-Centered Tailoring of Pediatric Diabetes Self-Management Resources
Status: Enrolling
Updated: 8/10/2017
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Tailored Diabetes Self-Management Resources
Family-Centered Tailoring of Pediatric Diabetes Self-Management Resources
Status: Enrolling
Updated:  8/10/2017
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Tailored Diabetes Self-Management Resources
Family-Centered Tailoring of Pediatric Diabetes Self-Management Resources
Status: Enrolling
Updated: 8/10/2017
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Diabetes Scorecard Educational Intervention Study
Use of a Card to Improve Risk Factor Control in Patients With Type II Diabetes
Status: Enrolling
Updated:  8/10/2017
Medical Faculty Associates at George Washington University
mi
from
Washington, D.C.,
Diabetes Scorecard Educational Intervention Study
Use of a Card to Improve Risk Factor Control in Patients With Type II Diabetes
Status: Enrolling
Updated: 8/10/2017
Medical Faculty Associates at George Washington University
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of A High-Fat Meal on the Pharmacokinetics of Bexagliflozin in Healthy Subjects
Status: Enrolling
Updated:  8/21/2017
Denver Clinical Research Unit
mi
from
Lakewood, CO
Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of A High-Fat Meal on the Pharmacokinetics of Bexagliflozin in Healthy Subjects
Status: Enrolling
Updated: 8/21/2017
Denver Clinical Research Unit
mi
from
Lakewood, CO
Click here to add this to my saved trials
Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects
Status: Enrolling
Updated:  8/21/2017
Clinical Research Site
mi
from
Evansville, IN
Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects
Status: Enrolling
Updated: 8/21/2017
Clinical Research Site
mi
from
Evansville, IN
Click here to add this to my saved trials
Families Preventing Diabetes Together
Families Preventing Diabetes Together
Status: Enrolling
Updated:  8/23/2017
University of Minnesota, School of Nursing
mi
from
Minneapolis, MN
Families Preventing Diabetes Together
Families Preventing Diabetes Together
Status: Enrolling
Updated: 8/23/2017
University of Minnesota, School of Nursing
mi
from
Minneapolis, MN
Click here to add this to my saved trials